In general, systemic administration of recombinant human IGF-1 may reduce the levels of insulin and glucose in diabetes patients with reduced response to insulin, which indicates that IGF-1 is capable of increasing insulin sensitivity [50] and has broad effects on IR and hyperglycemia. Here, IGF1 is linked to diabetes mellitus.